|
Friday 1st February 2002 |
Text too small? |
Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.
"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.
CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.
No comments yet
January 22nd Morning Report
TGG - FY 2025 Earnings Guidance Update
Meridian Energy monthly operating report for December 2025
January 21st Morning Report
PEB - Q3 26 Results and Key Strategic Milestones
FBU - Fletcher Building announces sale of Fletcher Construction
A thank you from Stuff's owner and publisher
FPH Appoints New Director and Future Director
January 19th Morning Report
January 15th Morning Report